Ariza, Celedenio P.
HRN: 24-46-18 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/10/2024
CO-AMOXICLAV 625MG (TAB)
03/10/2024
03/17/2024
ORAL
625mg
TID
Cap MR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes